|
1) Van Doorn P, Ruts L, Jacobs B. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008; 7: 939-50
|
|
|
|
2) Kusunoki S, Kaida K, Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: New aspects of research. Biochim Biophys Acta. 2008; 1780: 441-4
|
|
|
|
|
|
3) Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. J Neuroimmunol. 2010; 223: 5-12
|
|
|
|
|
|
4) Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies. Neurology. 1993; 43: 1911-7
|
|
|
|
|
|
5) Hakomori S. The glycosynapse. Proc Natl Acad Sci U S A. 2002; 99: 225-32
|
|
|
|
|
|
6) Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997; 387: 569-72
|
|
|
|
|
|
7) Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol. 2004; 56: 567-71
|
|
|
|
|
|
8) Kaida K, Morita D, Kanzaki M, et al. Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol. 2007; 182: 212-8
|
|
|
|
|
|
9) Kaida K, Sonoo M, Ogawa G, et al. GM1/GalNAc-GD1a complex: A target for pure motor Guillain-Barré syndrome. Neurology. 2008; 71: 1683-90
|
|
|
|
|
|
10) Hadden RDM, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome: Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol. 1998; 44: 780-8
|
|
|
|
|
|
11) Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995; 118: 597-605
|
|
|
|
|
|
12) Capasso M, Caporale CM, Pomilio F, et al. Acute motor conduction block neuropathy: another Guillain-Barré syndrome variant. Neurology. 2003; 61: 617-22
|
|
|
|
|
|
13) Kaida K, Kanzaki M, Morita D, et al. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 2006; 77: 1043-6
|
|
|
|
|
|
14) Kanzaki M, Kaida K, Ueda M, et al. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2008; 79: 1148-52
|
|
|
|
|
|
15) Ogawa G, Kaida K, Kusunoki S, et al. Antibodies to ganglioside complexes consisting of asialo-GM1 and GQ1b or GT1a in Fisher and Guillain-Barré syndromes. J Neuroimmunol. 2009; 214: 125-7
|
|
|
|
|
|
16) Kuijf, ML, Godschalk, PC, Gilbert, M, et al. Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol. 2007; 188: 69-73
|
|
|
|
|
|
17) Nobile-Orazio E, Giannotta C, Briani C. Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immunemediated neuropathies. J Neuroimmunol. 2009; 219: 119-22
|
|
|
|
|
|
18) Kaida, K, Kamakura, K, Ogawa, G, et al. GD1b-specific antibody induces ataxia in Guillain-Barré syndrome. Neurology. 2008; 71: 196-201
|
|
|
|
|
|
19) Kusunoki S, Shimizu J, Chiba A, et al. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol. 1996; 39: 424-31
|
|
|
|
|
|
20) Greenshields KN, Halstead SK, Zitman FM, et al. The neuropathic potential of anti-GM1 autoantibodies is required by the local glycolipid environment in mice. J Clin Invest. 2009; 119: 595-610
|
|
|
|
|
|
21) Todeschini AR, Dos Santos JN, Handa K, et al. Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc Natl Acad Sci U S A. 2008; 105; 1925-30
|
|
|
|
|
|
22) Takada K, Shimizu J, Kusunoki S. Apoptosis of primary sensory neurons in GD1b-induced sensory ataxic neuropathy. Exp Neurol. 2008; 209: 279-83
|
|
|
|
|